Shanghai Fosun Pharmaceutical(02196): FXS0683 receives approval for clinical trials.

Shanghai Fosun Pharmaceutical (02196) announced that its subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials of FXS0683 for hematologic malignancies. Shanghai Fosun Pharmaceutical Industry intends to conduct Phase I clinical studies of FXS0683 in China once the conditions are met. FXS0683 is an orally administered small molecule innovative drug independently developed by the group, which is a potent and highly selective new generation Bcl-2 inhibitor intended for the treatment of hematologic malignancies. FXS0683 targets and inhibits the activity of wild-type and mutant Bcl-2 proteins, promoting apoptosis of tumor cells and inhibiting tumor cell proliferation and growth. As of February 2026, the group's accumulated research and development investment for FXS0683 is approximately RMB 27 million (unaudited). According to the latest IQVIA CHPA data, in 2025, sales of Bcl-2 inhibitors in China were approximately RMB 338 million.